Over the past year, Viz.ai has launched AI-driven software for helping diagnose aortic disease, pulmonary embolism, and cerebral aneurysms, and it has a product pending 510(k) clearance for subdural hematoma.
The company received its first five CE Marks in 2021, followed by contracts with several leading hospitals. The number of hospitals using the Viz Platform recently surpassed the 1,000 mark, Viz.ai said. The company added that it has grown from 180 employees to more than 350 over the past 12 months, and it is planning to grow by nearly 200 people over the next 12 months.
Go to publisher site for the complete article: